Consolidated Statements of Stockholders' Deficit - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Stock Issuable [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 5,590	$ 326,705	$ 16,000	$ 27,392,125	$ (29,761,287)	$ (2,020,867)
Balance, shares at Dec. 31, 2017	5,589,647	326,705,526
Implementation of revenue recognition standard					51,148	51,148
Beneficial conversion features				93,000		93,000
Conversion of convertible debt		$ 3,000		(1,440)		$ 1,560
Conversion of convertible debt, shares		3,000,000				3,000,000
Disposal of Medical Therapeutics subsidiary				3,036		$ 3,036
Net income (loss)					918,238	918,238
Balance at Dec. 31, 2018	$ 5,590	$ 329,705	16,000	27,486,721	(28,791,901)	(953,885)
Balance, shares at Dec. 31, 2018	5,589,647	329,705,526
Beneficial conversion features				206,000		206,000
Conversion of convertible debt		$ 231,210		177,293		$ 408,503
Conversion of convertible debt, shares		231,210,201				232,210,201
Shares subscribed in private placement			4,500			$ 4,500
Net income (loss)					(1,238,976)	(1,238,976)
Balance at Dec. 31, 2019	$ 5,590	$ 560,915	$ 20,500	$ 27,870,014	$ (30,030,877)	$ (1,573,858)
Balance, shares at Dec. 31, 2019	5,589,647	560,915,727